Sumary of COVID-19: Tsunami of chronic health conditions expected, research and health care disrupted:
- These are the opinions of two esteemed leaders in cardiovascular disease care, research and strategy, detailed in two new Frame of Reference articles published today in the American Heart Association’s flagship journal Circulation..
- It has prompted urgent responses in many sectors that could be models for rapidly developing real-world solutions that can improve efforts focused on prevention of chronic health conditions..
- He is the head of clinical policy and strategy at Verily Life Sciences and Google Health, a former commissioner of the U.S..
- Food and Drug Administration, former vice chancellor for health data science at Duke University School of Medicine and the founding director of the Duke Clinical Research Institute..
- Califf also notes the impacts of structural racism and that social determinants of health must be incorporated at all levels of research, clinical care and within communities and society at large for equitable, systemic improvement in health outcomes to be realized..
- to be a speedy, prioritized clinical trial infrastructure that assesses the risks and benefits of new therapies compared to existing therapies for chronic health conditions..
- This would allow the vast pool of clinical trials to be more focused on immediate interventions that can improve prevention, care and outcomes..
- Notably, she was an author of the Association’s 2007 Guidelines for Cardiovascular Disease in Women, and she has received multiple awards from the Association including the Gold Heart Award, the Lifetime Achievement Award and, most recently, the 2020 Eugene Braunwald Academic Mentorship Award….